Oliver Venture (@_OliverVenture) header
Oliver Venture (@_OliverVenture) profile picture

Discerning investor seeking market-disrupting innovators poised for substantial long-term appreciation | Sharing what I learn | Engagement welcomed | NFA

Connecticut
Joined January 2023
Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)Photo by Oliver Venture (@_OliverVenture)
Replying to @_OliverVenture
$NET $APP $NVDA $TEM $PLTR $SNOW $BEAM $COHR $NTLA $SKHY $DUOL $AFRM $VICR $MRVL $UBER $IOT $NAMS $IREN $HIMS $SANA $CAVA Since last update: Trimmed $NET and $PLTR. Never thought and didn't intend for NET to be this big. Exited $PRCT (-20%) and $SYM (-7%). Moved all that into $COHR, $MRVL, $SKHY, and added to $VICR.
1
2
915
Oliver Venture retweeted
First prescription for Ubeslo in Germany . A great milestone for the New Amsterdam Pharma and Menarini partnership!
1
12
1
52
2,489
$NVDA total mystery who is "behind it"
Whoever is behind this coordinated reputation campaign to bury Jensen, I pray it backfires. The people behind this are 1/100th the leader Jensen is. The world is far better off with Jensen in his position than the scumbag power leeches who thirst to control what he built And yes I’m aware that he gave them an opening with his own poor decisions and character flaws, and I’d still rather his character flaws and leadership ability than theirs
2
2
465
$NTLA A one-time ~4 hour therapy of Lonvo-z for patients with HAE means: - transformational reset for family planning - paying it forward for children, current and future generations - reclaiming mental bandwidth (87% reported that they never think about HAE after treatment) - overcoming inferiority, shame, embarrassment - the end of hyper vigilance - the end of lifetime medication - deleting injection and dosing schedules - goodbye to insurance delays, denials - unrestricted travel - spontaneity - pursuing career and social opportunities - zero symptoms, zero treatments, and HAE being absent from life (86% of participants) - in effect — being cured.
4
21
1,057
$NTLA "We saw considerable patient interest in this trial. However, as we were among the last centers to come online, we were only able to screen and enroll one of our patients. This participant had type 1 HAE with frequent and severe angioedema attacks. She had cycled through a number of LTP therapies since her diagnosis and was continuing to experience breakthrough attacks. We discussed her treatment options, which included other approved LTPs in clinical development, and lonvo-z. Ultimately, she decided to enter HAELO for a couple of reasons. First, based on the clinical data that had been reported at that time, she saw the potential for this therapy to reduce her HAE attacks and the burdens associated with taking chronic medicine. Just as importantly, she also wanted to do this for her young son, who also has HAE. She saw the trial as a way to pay it forward and contribute to a potential path for him and others to have a better life than she experienced with HAE up until that point. This participant was dosed in the summer of 2025, and she says that she's benefited tremendously from lonvo-z. She actually has described her participation in HAELO, and these are her own words, as a, quote, "life-changing event." —Dr. Marc Riedl, Professor of Medicine at UC San Diego and Clinical Director of the HAEA Angioedema Center, during the HAE study update 💪
9
4
1
35
1,827
$MRNA got a monster pop for the perception that maybe if you squint your eyes they'd cured cancer. What's the pop for the company that actually cures type 1 diabetes? $SANA
1
8
878
$NTLA "I think what stands out to me mostly is that we did an analysis amongst patients about their having children, and up to 40% of patients in the past decided to refrain from having children because of the severity of their condition. But now with these kinds of treatments on the horizon, this has shifted tremendously, and now patients are having children even though they have a 50% chance of passing on the condition. But they think that with these perspectives, they feel pretty confident now that their children won't have to face the same issues that they had." —Danny Cohn, Internist Amsterdam University Medical Center, during the HAE study update.
1
3
20
1,966
$NTLA "As of today, we have dosed more than 600 patients with our investigational in vivo gene editing therapies. We believe this is more than all other companies in the world combined. We have up to six years of follow-up on some of these patients, and very importantly, we have yet to see any waning of pharmacodynamic or clinical effect." —John Leonard President and CEO, during the HAE study update.
10
19
6
113
20,075
*According to reports* Sleeps with customer. Sleeps with direct report. Sleeps with another employee. God knows what else. Admits to it Resigns Says he is a piece of shit FinX: Mad at (checks notes) board. $NVDA
256
"Dana White will be an Nvidia CEO like none other! Dana, please take the job!" $NVDA
1
231
Do not hire or even consider Sridhar Ramaswamy, I'm begging you. $NVDA $SNOW
1
369
We haven't hit the threshold for number of affairs to be desensitized yet. $NVDA
1
250
Adds criteria to investment models: - Is CEO full of rizz likely YOLO honeypot target?
217
👏👏👏
📢 $NTLA News: We’re excited to share Intellia has completed enrollment in MAGNITUDE-2, our Phase 3 trial investigating the one-time treatment of patients with #ATTR #amyloidosis with polyneuropathy. Read the press release: ir.intelliatx.com/news-relea…
6
344
Increased $MRVL position. Undecided on $COHR.
1
346
Pretty much exactly this LOL! $SKHY
오늘 하이닉스 3분기 어닝콜 요약 우리 실적 미쳤어. 그리고 28년까지 장기계약 50% 이상 했어. 그리고 29년까지 사실상 DRAM과 HBM 물량은 솔드아웃이야. 그리고 지금 수요가 넘쳐나는데, 너네가 혹시나 걱정하는 수요 감소의 경우에는 걱정할 필요가 없는 게 지금 빅테크뿐만 아니라 전 세계 모든 나라에서 AI를 구축하려고 해. 그 수요가 엄청나. 그리고 캐파 늘린다고 공급이 늘 거라 걱정하는데, HBM 같은 고부가가치 제품 때문에 공정이 더 복잡해져서 공급이 늘기 힘들어. 그리고 씨발, 우리가 빅테크한테 한두 번 속아보냐? 니네가 필요하다고 해서 바로 캐파 안 늘리고, 니네 재무제표부터 다 뜯어보고 캐파 늘려. 구라치다 걸리지 마라. 그리고 니네가 걱정하는 HBM4는 수율이 계획보다 잘 나와서 목표도 상향했고 4분기부터 출하해. HBM4E도 이미 2분기에 샘플 보냈고 순조롭게 잘되고 있어. 적층 단수 내린 거? 적층 단수를 내려야 그나마 부족한 공급을 늘릴 거 아니야. 그리고 4F²? 제발 기술 구현과 상용화 개념 좀 알고 이야기해.
220
$BEAM "I think if there is a general just kind of comment that I have that I think these LNPs are really doing quite well. This is a great delivery modality where we are talking about temporary headache, fever, flush kinds of infusion reactions or lab abnormalities in return for a one-time dose that gets you potentially transformative durable efficacy like we are seeing here. It is a pretty good delivery vehicle. We are quite happy with it." —John Evans, CEO, this morning throwing shade at analysts who are obsessed with the transient side effects of LNPs at dosing vs the permanent effect of the therapy: being cured of their genetic disease.
1
1
19
3,156
NotebookLM for research (10k, 10Q, transcripts, study updates/presentations), but "hire" Muse to gather/update sources.
199
Will kickflip and barrel roll be in the Halloween update for $TSLA model 3? Asking for a friend....
1
298
Tesla has figured out hire to make cars fly, but auto wiper technology still more difficult than getting to the moon.
3
295
$ARWR "Yeah, I think the BIlB080 program, look, I thought those data were generally supportive. The phase II data, I know there was some questions around their inverse or lack of dose response. But at the end of the day, they showed reductions in CSF tau that corresponded to an improvement in tau PET, and that corresponded to improvements in multiple different clinical rating scales. All in all, we thought those were positive and supportive of the tau hypothesis. Now, those were with an ASO, an intrathecally administered ASO. We're of the belief that not only that route of administration, but the ASO may lead to some safety issues which could have muddied the water on the cognitive rating scale efficacy side of things. In terms of what we're looking for, we feel like we at least need to achieve knockdown on par with what BIIB080 achieved, so 50%-60%. It's unclear if that's sort of the sweet spot or if more knockdown you'd see more improvements. One thing to consider additionally is if you administer the drug with an intrathecal route, the distribution's really heterogeneous." —James Hamilton, CMO and Head of R&D at HC Wainwright Investment Conference
8
859